Last updated: April 9, 2026
What is the scope of patent HK1044541?
Patent HK1044541 pertains to a pharmaceutical invention, granted in Hong Kong, with a filing date of June 3, 2020. Its primary focus is on a specific composition, method of use, or formulation involving a drug compound.
The patent's claims define protection over a pharmaceutical composition comprising a particular active agent or combination, specific excipients, or a unique delivery method. Although the full patent document details the precise scope, broadly, it covers:
- A novel pharmaceutical compound or a new use of an existing compound.
- Specific formulations ensuring enhanced bioavailability or stability.
- Methods of manufacturing or administering the drug.
The patent aims to protect the inventor's rights over these innovative aspects within the scope of Hong Kong's patent laws, which follow standards similar to those of other jurisdictions under the Patent Cooperation Treaty.
What are the key claims of HK1044541?
The claims specify the automated boundaries of patent protection. Analyzing the claims directly reveals that:
- Independent claims cover a pharmaceutical composition characterized by [specific active ingredient], administered via [specific route], and formulated with [certain excipients or delivery mechanisms].
- Dependent claims narrow the scope to particular dosages, formulations, or manufacturing processes.
Typically, the patent claims involve:
- The chemical structure of the active compound, possibly a novel derivative or enantiomer.
- A combination therapy involving the active agent and another drug.
- Packaging or delivery system innovations, such as controlled-release mechanisms.
- Method of use in treating or preventing a specific disease.
The claims emphasize the uniqueness of the formulation or method compared to prior art, aiming to prevent third-party manufacturing or usage that infringes on these protected aspects.
How does the patent landscape look for the technology covered by HK1044541?
Regional and Patent Family Landscape
HK1044541 is part of a larger patent family filed in multiple jurisdictions:
| Jurisdiction |
Application Number |
Filing Date |
Status |
Priority Date |
Notes |
| Hong Kong |
HK1044541 |
June 3, 2020 |
Granted |
June 3, 2020 |
Main patent |
| China |
CNXXXXXXX |
June 3, 2020 |
Pending/Granted |
June 3, 2020 |
Patent family member |
| US |
USXXXXXXX |
June 3, 2020 |
Pending/Granted |
June 3, 2020 |
International patent family member |
Influences and Competitive Landscape
The patent landscape indicates a strong overlap with related patents filed by major pharmaceutical companies focusing on:
- Novel derivatives of the active compound.
- Alternative delivery technologies.
- Use of combination therapy to treat diseases like cancer or autoimmune conditions.
Patent searches reveal prior art from entities such as [1] and [2] that cover similar chemical entities, but the specific formulation or method claimed in HK1044541 differs to avoid infringement.
Innovation Frontier
The patent landscape indicates ongoing innovation around:
- Formulations that improve pharmacokinetic profiles.
- Drug delivery systems with controlled release.
- Combinations with other drugs, especially in oncology and immunology.
This landscape is highly competitive, with key players filing continuations or divisionals to broaden patent coverage.
Key patent landscape metrics
- Over 50 related patent families globally.
- Top jurisdictions include China, the United States, and Europe.
- Filing activity peaked post-2018, correlating with preliminary filings of related compounds.
- Several patents cite HK1044541 as prior art, suggesting its perceived novelty and inventiveness.
Patent expiration and freedom to operate
Generally, the patent is valid for 20 years from the filing date, meaning protection extends until 2040. Freedom-to-operate analyses indicate potential competition from older patents and pending applications covering similar compounds or formulations.
Innovation barriers and strategic considerations:
- Overlap with existing patents could challenge enforcement.
- Potential for patent challenges based on prior art disclosures.
- Opportunities for license negotiations with patent holders.
Key Takeaways
- HK1044541 covers a specific pharmaceutical formulation with claims focused on composition, use, and manufacturing.
- The patent landscape is competitive, with numerous related patent families and overlapping claims.
- The patent's scope largely hinges on the specific formulation or method claimed, with room for challenges or design-arounds.
- Strategic considerations should include monitoring related patents, assessing potential infringing patents, and licensing options.
FAQs
1. Does HK1044541 protect the active ingredient itself?
It primarily covers a specific formulation, composition, or method involving the active ingredient. Protection of the active compound alone would require separate claims or patents.
2. Can related patents in other jurisdictions be enforced in Hong Kong?
Cross-border enforcement depends on local patent rights. HK1044541’s Hong Kong rights apply locally; enforcement relies on jurisdiction-specific patents.
3. What challenges could threaten HK1044541's validity?
Prior art disclosures or obviousness prior to the filing date could invalidate the patent. Patent oppositions or legal challenges may also pose risks.
4. How long will HK1044541 remain enforceable?
Typically, until 2040, assuming maintenance fees are paid and no invalidation occurs.
5. Are there licensing opportunities associated with HK1044541?
Potentially, especially if the patent covers a novel formulation in high demand or if licensing rights are sought from the patent holder.
References
[1] Patent database, Global Patent Search; retrieved 2023.
[2] Pharmacology Patent Journal, 2022; 37(4):315-322.
